Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 19, 2004Clinical Infectious DiseasesOpen Access

Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShyam SundarHMHimanshu MehtaASAkhil Suresh

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sundar et al. (2004) studied this question.

synapsesocial.com/papers/6a9c8ad3cd2fcf852aacb2echttps://doi.org/10.1086/380971
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Socio-economics of visceral leishmaniasis in Bihar (India)2000 · 108 citations
  2. 2Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trialCommentary: cost and resistance remain issues2001 · 167 citations
  3. 3Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases1999 · 145 citations
  4. 4Short-Course, Low-Dose Amphotericin B Lipid Complex Therapy for Visceral Leishmaniasis Unresponsive to Antimony1997 · 103 citations